Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 26, 2015
Pharmacy Choice - News - Front Page Healthcare News - January 26, 2015

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/26/15 - 3SBio Acquires Sirton Pharmaceuticals SpA
SHENYANG, China and VILLA GUARDIA, Italy, Jan. 25, 2015/ PRNewswire/ 3 SBio Inc., "3 SBio", a leading China- based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that on December 31, 2014, 3 SBio acquired the entire share capital of Sirton Pharmaceuticals SpA from
1/26/15 - Actinium Submits Pre-IND Meeting Request to the U.S. FDA for its Iomab-B Drug Candidate
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a pre-IND meeting to the U.S. Food and Drug Administration for the company's Iomab-B drug candidate currently undergoing final preparations..
1/26/15 - Agency Forms Submitted for OMB Review, Request for Comments
SUMMARY: In accordance with the Paperwork Reduction Act of 1995, the Railroad Retirement Board is forwarding an Information Collection Request to the Office of Information and Regulatory Affairs, Office of Management and Budget. Our ICRdescribes the information we seek to collect from the public. Review and approval by OIRA ensures that we impose..
1/26/15 - ALK's partner, Torii, submits registration application for the house dust mite SLIT-tablet in Japan
ALK's partner for Japan, Torii Pharmaceutical Co. Ltd., has submitted a registration application- a New Drug Application- to the Japanese Ministry of Health, Labour and Welfare, for ALK's house dust mite sublingual allergy immunotherapy tablet. Jens Bager, ALK's President and CEO, said: " This regulatory submission in Japan represents a major step
1/26/15 - Antares Pharma Gets Complete Response Letter For Sumatriptan Injection USP
PETAH TIKVA- Antares Pharma Inc. announced that the U.S. Food and Drug Administration or FDA has issued a complete response letter regarding the Abbreviated New Drug Application or ANDA for Sumatriptan Injection USP for the acute treatment of migraine. The complete response letter from the FDA provided revisions to labelling and cited minor deficie
1/26/15 - Antares Pharma Provides Regulatory Update on Sumatriptan Injection USP
Antares Pharma, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the Abbreviated New Drug Application for Sumatriptan Injection USP for the acute treatment of migraine. As previously disclosed, Teva Pharmaceutical Industries, Ltd. would distribute the product and share the profits equal
1/26/15 - Axion Power Announces the Appointment of Donald F. Farley to its Board of Directors
By a News Reporter-Staff News Editor at Pharma Business Week Axion Power International, Inc., a developer of advanced lead-carbon PbC batteries, energy storage systems and frequency regulation systems, announced that Donald F. Farley, 72, has been appointed to its Board of Directors, effective January 10, 2015. As president of Farley& Associat
1/26/15 - Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis as Chairman of the Board
"We are enthusiastic to have the opportunity to work with Dr. Lewis in his new capacity as Chairman of the Board. Given the recent filing of an IND with the FDA to initiate a dose escalating Phase I/II clinical trial in lung cancer, we believe that having a Chairman with the industry experience of Dr. Lewis will strategically position Batu Biologic
1/26/15 - Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals
By a News Reporter-Staff News Editor at Biotech Business Week Biogen Idec announced that it has agreed to acquire U.K.- based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain. Biogen Idec plans to leverage Convergence's expertise
1/26/15 - Caligor Names Karen Frascello Vice President of Business Development & Marketing, Global Access Programs
By a News Reporter-Staff News Editor at Biotech Business Week Before joining Caligor, Ms. Frascello served as Director of Global Business Development at Idis Inc., where she guided pharma and biotech companies through the strategic planning process for developing global patient access and compassionate use programs. Ms. Frascello had oversight fo
1/26/15 - Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, is pleased to announce that it is submitting a request early this week to the Food and Drug Administration Division of Gastroenterology and Inborn Errors Products to conduct a...
1/26/15 - Centene Corporation To Acquire Oregon-Based Agate Resources
Centene Corporation announced today that it has signed a definitive agreement to acquire Agate Resources, Inc., a diversified holding company that offers an array of healthcare products and services to Oregon residents. Trillium Community Health Plan, Inc., a subsidiary of Agate, participates in Oregon's Coordinated Care Organization model to pro
1/26/15 - Clinical Trail Finds Kids' Growth Impacted by Intranasal Corticosteroids
An Allegheny Health Network clinical trial examining whether intranasal corticosteroids stunt children's growth the first such trial conducted in accordance with U.S. Food and Drug Administration guidelines- found a small but statistically significant growth reduction for children taking the medication to treat allergic rhinitis, or hay fever.
1/26/15 - CVS Health Research Institute Provides More Evidence that Broader Prescription Drug Coverage Improves Health Outcomes
By a News Reporter-Staff News Editor at Managed Care Weekly Digest- A new analysis by researchers at Brigham and Women's Hospital and the CVS Health Research Institute, published on-line first in the American Journal of Public Health, shows that enhanced prescription drug insurance can improve patient health outcomes and reduce use of other, ofte
1/26/15 - Data from Gifu University Hospital Provide New Insights into Cirrhosis of the Liver (Sarcopenia impairs prognosis of patients with liver cirrhosis)
By a News Reporter-Staff News Editor at Gastroenterology Week Current study results on Liver Diseases and Conditions have been published. According to news reporting originating from Gifu, Japan, by NewsRx correspondents, research stated, "Sarcopenia is characterized by the loss of skeletal muscle mass, and is reported to appear in patients with
1/26/15 - DaVita Ranks First in Clinical Outcomes According to Government Reports
"For 15 years clinical quality has always been the first order of business at DaVita," said DaVita HealthCare Partners Co-Chairman and CEO Kent Thiry. CMS Quality Incentive Program According to the QIP results, released by CMS in mid-January, DaVita ranked first in three of four clinical measures in the ESRD program. This is the second straight yea
1/26/15 - EMA, NCI, and EORTC agree on IBCD, a first of its kind meeting
By a News Reporter-Staff News Editor at Clinical Trials Week The EORTC is proud to announce the signing of an agreement with the US National Cancer Institute, and the European Medicines Agency to produce a first of its kind meeting to collaboratively explore current issues in cancer drug development. Denis Lacombe, EORTC Director and Co-Chair of
1/26/15 - EnteroMedics Announces FDA Approval of VBLOC Vagal Blocking Therapy for the Treatment of Obesity
By a News Reporter-Staff News Editor at Clinical Trials Week EnteroMedics Inc. announced that the U.S. Food and Drug Administration has approved VBLOC vagal blocking therapy, delivered via the Maestro System, for the treatment of adult patients with obesity who have a Body Mass Index of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39
1/26/15 - ERYTECH Announces Its Financial Calendar for 2015
By a News Reporter-Staff News Editor at Clinical Trials Week Regulatory News: ERYTECH Pharma, the French biopharmaceutical company that develops innovative' tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical needs, announces its financial calendar for 2015. February 10, 2015:. Publication of full yea
1/26/15 - European Markets Indicate Weak Open After Syriza Victory In Greece
PARIS- The European markets are poised for a lower open on Monday, as the victory of the anti-austerity Syriza party in Greece raised concerns about the country's continuity in the eurozone. On the corporate front, Sanofi and Regeneron Pharmaceuticals, Inc. said the US Food and Drug Administration has accepted for priority review the Biologics Lice
1/26/15 - FDA approves a second vaccine to prevent serogroup B meningococcal disease
Release date- 23012015- The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Bexsero is the second vaccine approved by the FDA in the past three months to prevent this disease. 'With today's approval o
1/26/15 - FDA Approves Antria Phase 2 Stem Cell Clinical Trials
By a News Reporter-Staff News Editor at Pharma Business Week Clinical research company Antria, Inc. announced that the United States Food and Drug Administration has approved the next step in medical research to help patients look younger using their own stem cells. Antria is the first company to gain FDA approval to initiate Phase 2 clinical tri
1/26/15 - FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema
BioCryst Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema. The Fast Track designation process of the FDA is designed to.
1/26/15 - FDA permits marketing of first system of mobile medical apps for continuous glucose monitoring
ENP Newswire- 25 January 2015. Release date- 23012015- The U.S. Food and Drug Administration today allowed marketing of the first set of mobile medical apps that allow people with diabetes to automatically and securely share data from a continuous glucose monitor with other people in real-time using an Apple mobile device such as an iPhone.
1/26/15 - Fitch: SCOTUS Extends Patent Benefit for Teva; Generics Lose for Now [Manufacturing Close - Up]
Notably, the U.S. Food and Drug Administration has not yet approved any submitted generic versions, even though market exclusivity under the original appeals court ruling expired in May 2014. In the meantime, Teva can keep working to convert patients to its less frequently administered 40 mg formulation. Teva exceeded initial expectations in 2014 a
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part I: Cardiovascular Disorders
This lesson is supported by:
RxSchool
Workplace Safety & Joint Commission Standards for Pharmacy Professionals
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415